A Phase 2, Randomized, Placebo-controlled, Single-blind Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Administered Concomitantly in Healthy Subjects Aged greater than or equal to 11 to less than 19 Years.

Trial Profile

A Phase 2, Randomized, Placebo-controlled, Single-blind Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Administered Concomitantly in Healthy Subjects Aged greater than or equal to 11 to less than 19 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs PF 5212366 (Primary) ; DTaP poliovirus vaccine
  • Indications Diphtheria; Meningococcal group B infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 30 May 2017 According to a Pfizer media release, the European Commission (EC) has approved TRUMENBA (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. Results from this study supported the approval.
    • 12 May 2014 According to the Pfizer media release, the trial results were presented at the 32nd Annual Meeting of the European Society for paediatric Infectious Disease (EPID 2014).
    • 09 May 2014 Results of this trial were presented at European Society for paediatric Infectious Disease (EPID 2014).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top